Cytosurge and Lexogen have launched the first commercial integrated Live-seq workflow, enabling repeated RNA sequencing of the same living cells with minimal invasiveness. This breakthrough preserves cell viability, allowing longitudinal tracking of gene expression changes over time. The method integrates FluidFM’s cytoplasmic sampling with Lexogen’s ultra-sensitive RNA library preparation. The platform offers unprecedented insights into cellular dynamics relevant to drug response, disease progression, and developmental biology.